A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer
Hiroyuki Yasuda, Eiki Ichihara, Jun Sakakibara‐Konishi, Yoshitaka Zenke, Shinji Takeuchi, Masahiro Morise, Katsuyuki Hotta, Mineyoshi Sato, Shingo Matsumoto, Azusa Tanimoto, Reiko Matsuzawa, Katsuyuki Kiura, Yuta Takashima, Seiji Yano, Junji Koyama, Takahiro Fukushima, Junko Hamamoto, Hideki Terai, Shinnosuke Ikemura, Ryo Takemura, Kōichi Goto, Kenzo Soejima
Topics & Concepts
OsimertinibMedicineLung cancerInternal medicineOncologynon-small cell lung cancer (NSCLC)Clinical trialEpidermal growth factor receptorCancerErlotinibA549 cellLung Cancer Treatments and MutationsLung Cancer Research StudiesMelanoma and MAPK Pathways